Last reviewed · How we verify
Long Term Follow-Up
Long Term Follow-Up is a Small molecule drug developed by Sentynl Therapeutics, Inc.. It is currently in Phase 2 development. Also known as: CUTX-101.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Long Term Follow-Up |
|---|---|
| Also known as | CUTX-101 |
| Sponsor | Sentynl Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo
- Caracterization of the Combined Alterations in Respiration and aROUSal in Patients With Drug-resistant EpiLepsy (NA)
- Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke (NA)
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (PHASE3)
- Construction and Analysis of a Risk Prediction Model for Acute Myocardial Infarction Based on Spatiotemporal Heterogeneous Data
- Long-term Effects of Early Shoulder Exercise After CIED Implantation (NA)
- Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation
- Understanding the Long-term Impact of COVID-19 in Adults
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long Term Follow-Up CI brief — competitive landscape report
- Long Term Follow-Up updates RSS · CI watch RSS
- Sentynl Therapeutics, Inc. portfolio CI
Frequently asked questions about Long Term Follow-Up
What is Long Term Follow-Up?
Who makes Long Term Follow-Up?
Is Long Term Follow-Up also known as anything else?
What development phase is Long Term Follow-Up in?
Related
- Manufacturer: Sentynl Therapeutics, Inc. — full pipeline
- Also known as: CUTX-101
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing